PDCD1 and cancer: PD-1/PD-L1 pathway is an important immune checkpoint, and blocking the PD-1/PD-L1 pathway with anti-PD-1/PD-L1 monoclonal antibody is one of the most important advances in the history of cancer therapy [39–41].